Glenview Trust Co Takes Position in Becton, Dickinson and Company $BDX

Glenview Trust Co acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel reports. The fund acquired 72,242 shares of the medical instruments supplier’s stock, valued at approximately $10,932,000.

Other institutional investors also recently modified their holdings of the company. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company during the third quarter worth $25,000. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $29,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $32,000. Finally, Meeder Asset Management Inc. grew its stake in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Barclays increased their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. Finally, TD Cowen increased their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $188.11 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $51.83 billion, a price-to-earnings ratio of 56.66, a P/E/G ratio of 13.41 and a beta of 0.19. The firm’s 50 day simple moving average is $165.23 and its 200 day simple moving average is $160.33. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,869 shares of company stock valued at $1,994,719 over the last quarter. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.